Hepatocellular Carcinoma — Asan Medical Center (AMC) Private Cohort

Overview

The lihc_amc_prv dataset is the Asan Medical Center (Seoul, Korea) hepatocellular carcinoma cohort, linked in the cBioPortal knowledge base. It is cited in a comprehensive molecular-landscape review of HCC by Llovet et al. (2018) that synthesises whole-exome sequencing data from 1,289 patients across multiple cohorts, including TCGA HCC (363 patients with all five molecular platforms), and SNP-array copy-number data from 704 patients.

Composition

  • Cancer types: [[cancer_types/HCC|HCC]] (hepatocellular carcinoma).
  • Molecular profiling integrated in the 2018 review: WES (n = 1,289 pooled), SNP-array CNAs (n = 704 pooled).
  • Largest single-institution genomic analysis cited: TCGA HCC (363 patients profiled across DNA copy number, methylation, mRNA, miRNA, RPPA platforms).

Assays / panels (linked)

  • Whole-exome sequencing
  • SNP-array copy-number profiling

Papers using this cohort

  • PMID:24798001 — Llovet et al., Nature Reviews Clinical Oncology 2018. Molecular therapies and precision medicine for hepatocellular carcinoma.

Notable findings derived from this cohort

  • [[genes/TERT|TERT]] promoter mutations are the single most frequent somatic alteration in HCC (54%, range 44–59% across 1,289 WES patients); [[genes/CTNNB1|CTNNB1]] activating mutations in 29%, [[genes/TP53|TP53]] LOF in 28% PMID:24798001.
  • High-level focal amplifications: [[genes/MYC|MYC]] 12%, [[genes/CCND1|CCND1]] 7%, [[genes/FGF19|FGF19]] 6%, [[genes/VEGFA|VEGFA]] 5% (n = 704 SNP-array patients) PMID:24798001.
  • Only ~25% of HCCs harbour potentially targetable driver alterations; the majority of trunk mutations (TERT promoter, CTNNB1, TP53, AXIN1, ARID1A, ARID1B) are not currently actionable PMID:24798001.
  • Two principal molecular subclasses identified: a proliferation class (~50%, enriched for TP53 inactivation, FGF19/CCND1 amplification, HBV aetiology, poor prognosis) and a non-proliferation class (~50%, canonical WNT via CTNNB1, higher TERT promoter mutation, HCV/alcohol aetiology, better prognosis) PMID:24798001.
  • Immune classification identifies ~30% of HCCs as an “immune class” with high [[genes/CD274|CD274]]/[[genes/PDCD1|PDCD1]] expression; ~25% as an “immune-excluded” class characterised by [[genes/CTNNB1|CTNNB1]] mutations and low T-cell infiltrate PMID:24798001.

Sources

  • cBioPortal studyId: lihc_amc_prv
  • Llovet JM et al. Molecular therapies and precision medicine for hepatocellular carcinoma. Nat Rev Clin Oncol. 2018. PMID:24798001.

This page was processed by entity-page-writer on 2026-05-11.